KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Gsk (GSK) Enterprise Value (2016 - 2026)

Gsk has reported Enterprise Value over the past 18 years, most recently at -$5.0 billion for Q1 2026.

  • For Q1 2026, Enterprise Value rose 22.18% year-over-year to -$5.0 billion; the TTM value through Mar 2026 reached -$5.0 billion, up 22.18%, while the annual FY2025 figure was -$5.2 billion, 10.56% up from the prior year.
  • Enterprise Value for Q1 2026 was -$5.0 billion at Gsk, up from -$5.2 billion in the prior quarter.
  • Over five years, Enterprise Value peaked at -$382.8 million in Q2 2022 and troughed at -$9.7 billion in Q4 2022.
  • A 5-year average of -$5.2 billion and a median of -$4.9 billion in 2024 define the central range for Enterprise Value.
  • On a YoY basis, Enterprise Value climbed as much as 29.0% in 2023 and fell as far as 1153.88% in 2023.
  • Year by year, Enterprise Value stood at -$9.7 billion in 2022, then grew by 27.54% to -$7.1 billion in 2023, then increased by 17.08% to -$5.9 billion in 2024, then rose by 10.56% to -$5.2 billion in 2025, then grew by 5.31% to -$5.0 billion in 2026.
  • Business Quant data shows Enterprise Value for GSK at -$5.0 billion in Q1 2026, -$5.2 billion in Q4 2025, and -$4.8 billion in Q3 2025.